ENSYSCE BIOSCIENCES, INC. Cash and Cash Equivalents, Period Increase (Decrease)
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$1.01 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-15.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2021-03-15
- ENSYSCE BIOSCIENCES, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-12-31 was -$4.29K.
- ENSYSCE BIOSCIENCES, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-09-30 was -$70.39K.
- ENSYSCE BIOSCIENCES, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-06-30 was -$44.07K.
- ENSYSCE BIOSCIENCES, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-03-31 was -$893.20K.
- ENSYSCE BIOSCIENCES, INC. cash and cash equivalents, period increase (decrease) for fiscal 2020 was -$1.01M.
- ENSYSCE BIOSCIENCES, INC. cash and cash equivalents, period increase (decrease) for fiscal 2019 was -$597.25K.
- ENSYSCE BIOSCIENCES, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$431.68K.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 1 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 4 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|---|---|
| 2020-12-31 | -$4.29K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | -$74.68K derived: sum of 2 quarters · filed 2021-03-15 | -$118.75K derived: sum of 3 quarters · filed 2021-03-15 | -$1.01M 10-K · filed 2021-03-15 | ||
| 2020-09-30 | -$70.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$114.46K derived: sum of 2 quarters · filed 2020-11-09 | -$1.01M 10-Q · filed 2020-11-09 | -$1.22M derived: sum of 4 quarters · filed 2021-03-15 | ||
| 2020-06-30 | -$44.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$937.27K 10-Q · filed 2020-08-07 | -$1.15M derived: sum of 3 quarters · filed 2021-03-15 | -$1.28M derived: sum of 4 quarters · filed 2021-03-15 | ||
| 2020-03-31 | -$893.20K 10-Q · filed 2020-05-07 | -$1.11M derived: sum of 2 quarters · filed 2021-03-15 | -$1.23M derived: sum of 3 quarters · filed 2021-03-15 | -$1.34M derived: sum of 4 quarters · filed 2021-03-15 | ||
| 2019-12-31 | -$212.78K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | -$341.01K derived: sum of 2 quarters · filed 2021-03-15 | -$445.44K derived: sum of 3 quarters · filed 2021-03-15 | -$597.25K 10-K · filed 2021-03-15 | ||
| 2019-09-30 | -$128.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$232.67K derived: sum of 2 quarters · filed 2020-11-09 | -$384.47K 10-Q · filed 2020-11-09 | -$480.34K derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-06-30 | -$104.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$256.24K 10-Q · filed 2020-08-07 | -$352.11K derived: sum of 3 quarters · filed 2020-08-07 | -$320.20K derived: sum of 4 quarters · filed 2020-08-07 | ||
| 2019-03-31 | -$151.80K 10-Q · filed 2020-05-07 | -$247.67K derived: sum of 2 quarters · filed 2020-05-07 | -$215.76K derived: sum of 3 quarters · filed 2020-05-07 | -$396.07K derived: sum of 4 quarters · filed 2020-05-07 | ||
| 2018-12-31 | -$95.87K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | -$63.96K derived: sum of 2 quarters · filed 2020-03-10 | -$244.27K derived: sum of 3 quarters · filed 2020-03-10 | -$431.68K 10-K · filed 2020-03-10 | ||
| 2018-09-30 | $31.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$148.40K derived: sum of 2 quarters · filed 2019-11-07 | -$335.81K 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | -$180.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$367.71K 10-Q · filed 2019-08-07 | ||||
| 2018-03-31 | -$187.41K 10-Q · filed 2019-05-07 | |||||
| 2017-12-31 | $2.09M 10-K/A · filed 2019-03-12 | |||||
| 2017-09-30 | $340.00K 10-Q · filed 2018-01-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |